This is a preview of subscription content, log in via an institution to check access.
Notes
gross domestic product
Reference
Men P, et al. Cost-Effectiveness of Empagliflozin in Chinese Patients with Type 2 Diabetes and Established Cardiovascular Disease: a Discrete Event Simulation Economic Modelling Study. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PDB45, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80363?pdfid=54074
Rights and permissions
About this article
Cite this article
Empagliflozin cost effective for T2D + CV disease in China. PharmacoEcon Outcomes News 805, 16 (2018). https://doi.org/10.1007/s40274-018-5018-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5018-8